<!DOCTYPE html>
<html lang="zh-CN">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>vMTB Consultation Report | Unknown</title>
  <style>
    :root {
      --primary: #0d47a1;
      --secondary: #546e7a;
      --accent: #00838f;
      --warning: #f57c00;
      --danger: #c62828;
      --success: #2e7d32;
      --bg: #ffffff;
      --bg-alt: #f5f7fa;
      --text: #212121;
      --text-light: #616161;
      --border: #e0e0e0;
    }

    * { box-sizing: border-box; margin: 0; padding: 0; }

    body {
      font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", "Microsoft YaHei", sans-serif;
      background: var(--bg-alt);
      color: var(--text);
      line-height: 1.6;
      font-size: 14px;
      padding: 20px;
    }

    .container {
      max-width: 1100px;
      margin: 0 auto;
      background: var(--bg);
      box-shadow: 0 1px 3px rgba(0,0,0,0.1);
    }

    header {
      background: var(--primary);
      color: white;
      padding: 24px 32px;
      display: flex;
      justify-content: space-between;
      align-items: center;
    }

    header h1 {
      font-size: 20px;
      font-weight: 600;
      letter-spacing: 0.5px;
    }

    .header-meta {
      text-align: right;
      font-size: 12px;
      opacity: 0.9;
    }

    .section {
      padding: 24px 32px;
      border-bottom: 1px solid var(--border);
    }

    .section-title {
      font-size: 16px;
      font-weight: 600;
      color: var(--primary);
      margin-bottom: 16px;
      padding-bottom: 8px;
      border-bottom: 2px solid var(--primary);
    }

    h2 {
      color: var(--primary);
      font-size: 1.3em;
      margin-top: 24px;
      margin-bottom: 12px;
      padding-bottom: 8px;
      border-bottom: 2px solid var(--primary);
    }

    h3 {
      color: var(--secondary);
      font-size: 1.1em;
      margin-top: 16px;
      margin-bottom: 8px;
    }

    p { margin-bottom: 12px; }

    ul, ol {
      margin-left: 20px;
      margin-bottom: 12px;
    }

    li { margin-bottom: 6px; }

    /* Info Grid */
    .info-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
      gap: 16px;
    }

    .info-item {
      padding: 12px;
      background: var(--bg-alt);
      border-radius: 4px;
    }

    .info-item label {
      font-size: 11px;
      color: var(--text-light);
      text-transform: uppercase;
      letter-spacing: 0.5px;
      display: block;
      margin-bottom: 4px;
    }

    .info-item span { font-size: 14px; font-weight: 500; }

    /* Tables */
    table {
      width: 100%;
      border-collapse: collapse;
      font-size: 13px;
      margin: 16px 0;
    }

    th, td {
      padding: 10px 12px;
      text-align: left;
      border: 1px solid var(--border);
    }

    th {
      background: var(--bg-alt);
      font-weight: 600;
      color: var(--secondary);
    }

    tr:nth-child(even) { background: var(--bg-alt); }

    /* Badges */
    .badge {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 3px;
      font-size: 11px;
      font-weight: 600;
    }

    .badge-success { background: #e8f5e9; color: var(--success); }
    .badge-warning { background: #fff3e0; color: var(--warning); }
    .badge-danger  { background: #ffebee; color: var(--danger); }
    .badge-info    { background: #e3f2fd; color: var(--primary); }
    .badge-secondary { background: #eceff1; color: var(--secondary); }
    .badge-primary { background: var(--primary); color: white; }

    /* Executive Summary */
    .exec-summary {
      background: var(--bg-alt);
      padding: 20px;
      border-radius: 4px;
      border-left: 4px solid var(--primary);
      margin-bottom: 20px;
    }

    .exec-summary h3 {
      font-size: 14px;
      color: var(--primary);
      margin-bottom: 12px;
    }

    .exec-summary ul { list-style: none; padding: 0; margin: 0; }

    .exec-summary li {
      padding: 6px 0;
      border-bottom: 1px solid var(--border);
    }

    .exec-summary li:last-child { border-bottom: none; }

    /* Card Grid */
    .card-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
      gap: 16px;
      margin: 16px 0;
    }

    .card {
      border: 1px solid var(--border);
      border-radius: 4px;
      padding: 16px;
    }

    .card-header {
      font-weight: 600;
      color: var(--primary);
      margin-bottom: 12px;
      padding-bottom: 8px;
      border-bottom: 1px solid var(--border);
    }

    /* Treatment Timeline */
    .treatment-timeline {
      position: relative;
      padding-left: 60px;
      margin: 20px 0;
    }

    .treatment-timeline::before {
      content: '';
      position: absolute;
      left: 24px;
      top: 0;
      bottom: 0;
      width: 2px;
      background: var(--border);
    }

    .treatment-item {
      position: relative;
      margin-bottom: 16px;
      display: flex;
      align-items: flex-start;
    }

    .treatment-marker {
      position: absolute;
      left: -60px;
      width: 48px;
      height: 48px;
      background: var(--primary);
      color: white;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 600;
      font-size: 14px;
      z-index: 1;
    }

    .treatment-marker.event { background: var(--secondary); }
    .treatment-marker.adjuvant { background: #7e57c2; }
    .treatment-marker.maint { background: #26a69a; }
    .treatment-marker.pd { background: var(--danger); }
    .treatment-marker.current { background: var(--warning); color: var(--text); }
    .treatment-marker.surgery { background: var(--secondary); }
    .treatment-marker.neoadjuvant { background: var(--primary); }

    .treatment-content {
      flex: 1;
      background: var(--bg-alt);
      border-radius: 4px;
      padding: 12px 16px;
      border-left: 3px solid var(--primary);
    }

    .treatment-item.event .treatment-content { border-left-color: var(--secondary); }
    .treatment-item.adjuvant .treatment-content { border-left-color: #7e57c2; }
    .treatment-item.maint .treatment-content { border-left-color: #26a69a; }
    .treatment-item.pd .treatment-content { border-left-color: var(--danger); }
    .treatment-item.surgery .treatment-content { border-left-color: var(--secondary); }

    .treatment-header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      margin-bottom: 8px;
    }

    .treatment-date { font-weight: 600; color: var(--primary); }
    .treatment-body { font-size: 14px; }

    .treatment-note {
      font-size: 12px;
      margin-top: 6px;
      padding-left: 8px;
      border-left: 2px solid var(--border);
      color: var(--text-light);
    }

    /* Key Recommendations */
    .key-rec {
      display: flex;
      align-items: flex-start;
      padding: 12px;
      background: var(--bg-alt);
      margin-bottom: 8px;
      border-radius: 4px;
    }

    .key-rec-num {
      width: 24px;
      height: 24px;
      background: var(--primary);
      color: white;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 12px;
      font-weight: 600;
      margin-right: 12px;
      flex-shrink: 0;
    }

    /* Inline Citations with Tooltip */
    .cite {
      color: var(--primary);
      cursor: pointer;
      text-decoration: none;
      font-size: 11px;
      vertical-align: super;
      font-weight: 600;
    }
    .cite:hover { text-decoration: underline; }

    .ref-tooltip {
      position: relative;
      display: inline;
    }

    .ref-tooltip .ref-text {
      visibility: hidden;
      background: #333;
      color: #fff;
      padding: 10px 14px;
      border-radius: 6px;
      position: absolute;
      z-index: 100;
      bottom: 125%;
      left: 50%;
      transform: translateX(-50%);
      width: 350px;
      font-size: 12px;
      line-height: 1.5;
      white-space: normal;
      box-shadow: 0 4px 12px rgba(0,0,0,0.3);
    }

    .ref-tooltip .ref-text::after {
      content: '';
      position: absolute;
      top: 100%;
      left: 50%;
      margin-left: -6px;
      border-width: 6px;
      border-style: solid;
      border-color: #333 transparent transparent transparent;
    }

    .ref-tooltip:hover .ref-text { visibility: visible; }

    /* Evidence Tags */
    .evidence {
      font-size: 10px;
      padding: 1px 6px;
      border-radius: 2px;
      margin-left: 6px;
    }

    .evidence-high   { background: #c8e6c9; color: var(--success); }
    .evidence-medium { background: #fff9c4; color: #f57f17; }
    .evidence-low    { background: #ffcdd2; color: var(--danger); }

    .evidence-tag {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 4px;
      font-size: 11px;
      font-weight: 500;
      margin-left: 5px;
    }

    .evidence-a { background: #dcfce7; color: #166534; }
    .evidence-b { background: #dbeafe; color: #1e40af; }
    .evidence-c { background: #fef3c7; color: #92400e; }
    .evidence-d { background: #fee2e2; color: #991b1b; }

    /* Calculation Box */
    .calc-box {
      background: var(--bg-alt);
      padding: 16px;
      border-radius: 4px;
      font-family: "SF Mono", Monaco, monospace;
      font-size: 13px;
      margin: 12px 0;
    }

    .calc-box h4 {
      font-family: -apple-system, sans-serif;
      font-size: 13px;
      margin-bottom: 8px;
    }

    /* Drug Comparison Row */
    .drug-row {
      display: grid;
      grid-template-columns: 140px repeat(4, 1fr);
      gap: 1px;
      background: var(--border);
      margin-bottom: 16px;
    }

    .drug-row > div {
      background: var(--bg);
      padding: 10px;
      font-size: 13px;
    }

    .drug-row .drug-name {
      background: var(--primary);
      color: white;
      font-weight: 600;
    }

    /* Warning Box */
    .warning-box {
      background: #fef2f2;
      border-left: 4px solid var(--danger);
      padding: 15px 20px;
      margin: 20px 0;
      border-radius: 0 8px 8px 0;
    }

    .warning-box strong {
      color: var(--danger);
    }

    /* Info Box */
    .info-box {
      background: var(--bg-alt);
      border-left: 4px solid var(--primary);
      padding: 15px 20px;
      margin: 20px 0;
      border-radius: 0 8px 8px 0;
    }

    /* Utility Classes */
    .highlight { background: #fff9c4; padding: 0 2px; }
    .text-danger { color: var(--danger); }
    .text-success { color: var(--success); }
    .text-warning { color: var(--warning); }

    /* Reference Links */
    .reference {
      color: var(--primary);
      text-decoration: none;
      transition: color 0.2s;
    }

    .reference:hover {
      color: var(--accent);
      text-decoration: underline;
    }

    /* Footer */
    footer {
      padding: 16px 32px;
      background: var(--bg-alt);
      text-align: center;
      font-size: 11px;
      color: var(--text-light);
    }

    /* Print Styles */
    @media print {
      body { background: white; padding: 0; }
      .container { box-shadow: none; }
      .section { page-break-inside: avoid; }
      .ref-tooltip .ref-text { display: none; }
    }

    /* Content Area */
    .content {
      padding: 24px 32px;
    }
  </style>
</head>
<body>
  <div class="container">

    <!-- Header -->
    <header>
      <h1>虚拟分子肿瘤委员会会诊报告</h1>
      <div class="header-meta">
        <div>vMTB Consultation Report</div>
        <div>患者编号: Unknown</div>
        <div>肿瘤类型: 乙状结肠中分化腺癌</div>
        <div>报告日期: 2026-01-20 16:14:11</div>
      </div>
    </header>

    <!-- Report Content -->
    <div class="content">
      <p>这里是基于您提供的专家报告汇总生成的最终 MTB 报告。</p>
<hr />
<h1>分子肿瘤委员会 (MTB) 综合报告</h1>
<h2>1. 执行摘要 (Executive Summary)</h2>
<div class="exec-summary"><h3>执行摘要</h3><ul><li><strong>患者:</strong> 70岁男性，乙状结肠中分化腺癌，IV期 (ypT4aN2aM1)</li><li><strong>关键分子特征:</strong> KRAS G12C (11.5%), ATM 胚系突变, TMB-H (79 mut/Mb), MSS</li><li><strong>当前治疗:</strong> 氟泽雷赛 + 西妥昔单抗 (2025.10起，五线治疗)</li><li><strong>核心建议:</strong> 维持当前双靶方案，严密监测肾功能；后线优先考虑 Pan-KRAS 临床试验或 TAS-102</li><li><strong>紧急程度:</strong> 常规 (目前待评估，需关注肾毒性)</li></ul></div>

<p><strong>综合意见</strong>:<br />
患者为晚期结直肠癌，携带罕见的 <strong>KRAS G12C</strong> 突变及 <strong>ATM 胚系突变</strong>。尽管 TMB 极高 (79 mut/Mb)，但为 MSS 表型且既往免疫治疗获益有限，提示非典型免疫获益人群。目前正接受五线 <strong>氟泽雷赛 (KRAS G12C 抑制剂) 联合西妥昔单抗</strong> 治疗，这是基于机制最合理的方案 <span class="ref-tooltip">
              <a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/37870968" target="_blank">[R1]</a>
              <span class="ref-text">CodeBreaK 300: ORR 30%</span>
            </span> <span class="evidence-tag evidence-b">Evidence B</span>。</p>
<p><strong>主要风险</strong>: 患者存在 <strong>CKD 3b期肾功能不全 (eGFR ~40 mL/min)</strong> 及既往 TKI 相关急性肾损伤史。<strong>绝对禁忌</strong>再次使用呋喹替尼或瑞戈非尼。后续治疗需严格根据肾功能调整剂量。</p>
<hr />
<h2>2. 患者概况 (Patient Profile)</h2>
<h3>Demographics</h3>
<ul>
<li><strong>Age</strong>: 70 years</li>
<li><strong>Sex</strong>: Male</li>
<li><strong>ECOG PS</strong>: 1</li>
<li><strong>Height/Weight</strong>: 165cm / 66kg</li>
</ul>
<h3>Cancer Diagnosis</h3>
<ul>
<li><strong>Primary Cancer</strong>: 乙状结肠中分化腺癌</li>
<li><strong>Histology</strong>: 腺癌 (Adenocarcinoma)</li>
<li><strong>Stage</strong>: IV期 (ypT4aN2aM1) - 术后病理分期</li>
<li><strong>Metastatic Sites</strong>: 双肺多发转移 (最大 2.1×1.5cm)</li>
<li><strong>Tumor Markers</strong>: CEA 112 ng/mL (升高), CA-199 145 U/mL</li>
</ul>
<h3>Comorbidities</h3>
<ul>
<li><strong>Renal Impairment</strong>: 肌酐 146 μmol/L (eGFR ~39-44 mL/min)，既往 TKI 相关急性肾损伤</li>
<li><strong>Cardiovascular</strong>: 高血压 (硝苯地平)，心脏支架植入史 (阿托伐他汀)</li>
<li><strong>Endocrine</strong>: 糖尿病 (达格列净，阿卡波糖)</li>
</ul>
<hr />
<h2>3. 分子特征 (Molecular Profile)</h2>
<h3>3.1 主要驱动突变</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant</th>
<th>Type</th>
<th>VAF</th>
<th>Frequency (cBioPortal)</th>
<th>CIViC Level</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KRAS</strong></td>
<td><strong>G12C</strong></td>
<td>SNV</td>
<td>11.5%</td>
<td>3-4% in CRC</td>
<td>Level A (Combo)</td>
<td>[Evidence A/B]</td>
</tr>
<tr>
<td><strong>ATM</strong></td>
<td><strong>Germline</strong></td>
<td>Truncation</td>
<td>-</td>
<td>5-7%</td>
<td>Level C</td>
<td><span class="evidence-tag evidence-c">Evidence C</span></td>
</tr>
</tbody>
</table>
<p><strong>临床意义解读</strong>:<br />
1.  <strong>KRAS G12C</strong>: 核心治疗靶点。单药抑制会导致 EGFR 反馈性激活，必须联合抗 EGFR 单抗 (如西妥昔单抗) <span class="ref-tooltip">
              <a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/36546659" target="_blank">[R2]</a>
              <span class="ref-text">KRYSTAL-1: Combo ORR higher</span>
            </span>。<br />
2.  <strong>ATM (胚系)</strong>: 提示同源重组修复缺陷 (HRD)。解释了患者一线对奥沙利铂 (DNA损伤剂) 的敏感性 (PR, TRG2)。提示 PARP 抑制剂可能有效 (合成致死机制)。</p>
<h3>3.2 免疫治疗标志物</h3>
<ul>
<li><strong>MSI/MMR 状态</strong>: <strong>MSS / pMMR</strong> (微卫星稳定/错配修复完整)</li>
<li><strong>TMB</strong>: <strong>79 mut/Mb (High)</strong><ul>
<li><strong>病理分析</strong>: MSS 背景下的超高 TMB 高度提示 <strong>POLE/POLD1</strong> 突变 (超突变表型)。</li>
<li><strong>临床矛盾</strong>: 尽管 TMB 高，患者既往免疫联合治疗 (信迪利单抗) 仅获 SD 或 PD，未达深度缓解，提示可能存在免疫逃逸或假性高 TMB。</li>
</ul>
</li>
<li><strong>PD-L1</strong>: CPS = 3 (低表达)</li>
</ul>
<h3>3.3 阴性重要发现</h3>
<ul>
<li><strong>BRAF V600E</strong>: Negative (排除 BRAF 抑制剂)</li>
<li><strong>HER2</strong>: IHC 0 (排除抗 HER2 治疗)</li>
<li><strong>NRAS</strong>: Negative</li>
</ul>
<hr />
<h2>4. 治疗史回顾 (Treatment History)</h2>
<div class="treatment-timeline"><p>- line: 1线
  date: 2022.08-2022.12
  regimen: 奥沙利铂+卡培他滨+贝伐珠单抗 (5程)
  response: PR
  type: neoadjuvant
  note: 新辅助化疗，疗效显著

- line: 手术
  date: 2023.01
  regimen: 根治性手术
  response: TRG2
  type: surgery
  note: 切除原发灶+肝转移+淋巴结清扫；病理显示淋巴结 5/19(+)

- line: 1线(辅助)
  date: 2023.03-2023.05
  regimen: 奥沙利铂+卡培他滨 (3程)
  response: -
  type: adjuvant
  note: 术后辅助化疗

- line: 1线(维持)
  date: 2023.05-2023.08
  regimen: 卡培他滨单药
  response: -
  type: maint
  note: 维持治疗，双肺出现小结节

- line: 2线
  date: 2023.08-2024.01
  regimen: 伊立替康+亚叶酸钙+5-FU+贝伐珠单抗
  response: SD
  type: pd
  note: 疾病稳定

- line: 2线(维持)
  date: 2024.02-2024.06
  regimen: 卡培他滨单药
  response: -
  type: maint
  note: 维持治疗

- line: 3线
  date: 2024.07
  regimen: 呋喹替尼+信迪利单抗
  response: -
  type: event
  note: 严重不良反应：急性肾损伤+肢体水肿 (肾穿刺证实TKI相关)

- line: 3线(Re-challenge)
  date: 2024.09
  regimen: 雷替曲塞+信迪利单抗
  response: -
  type: event
  note: 出现发热，疑似感染

- line: 3线(Re-challenge)
  date: 2024.10-2025.02
  regimen: 雷替曲塞+信迪利单抗
  response: SD(缩小)
  type: pd
  note: 病情暂时控制，CEA 降至 17.2

- line: 4线
  date: 2025.02-2025.10
  regimen: 信迪利单抗+抗肿瘤新抗原mRNA疫苗 (含KRAS G12C抗原)
  response: PD
  type: pd
  note: 肺转移增大，CEA 升至 112；副作用：发热，II度血小板减少

- line: 5线(当前)
  date: 2025.10-今
  regimen: 氟泽雷赛+西妥昔单抗
  response: 待评估
  type: current
  note: 首次针对 KRAS G12C 靶向治疗</p></div>

<p><strong>Key Observations</strong>:<br />
1.  <strong>Platinum Sensitivity</strong>: 1L Oxaliplatin achieved PR/TRG2 (consistent with ATM mutation).<br />
2.  <strong>Renal Toxicity</strong>: Severe AKI with Fruquintinib (3L).<br />
3.  <strong>IO Resistance</strong>: Multiple IO lines (Sintilimab combos) failed to produce durable response despite high TMB.</p>
<hr />
<h2>5. 药物/方案对比 (Regimen Comparison)</h2>
<h3>5.1 方案对比表</h3>
<table>
<thead>
<tr>
<th>Regimen</th>
<th>Evidence Level</th>
<th>具体给药剂量</th>
<th>肾功能调整 (eGFR ~40)</th>
<th>ORR</th>
<th>mPFS</th>
<th>Key Toxicities</th>
<th>Access</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>氟泽雷赛 + 西妥昔单抗</strong> (Current)</td>
<td><strong>[B]</strong></td>
<td>氟: 600mg BID<br>西: 500mg/m² q2w</td>
<td>氟: 密切监测<br>西: 无需调整</td>
<td>~30%</td>
<td>~5.6m</td>
<td>腹泻, 皮疹, 低镁</td>
<td>中国上市/试验</td>
</tr>
<tr>
<td><strong>TAS-102 + 贝伐珠单抗</strong> (Next)</td>
<td><strong>[A]</strong></td>
<td>TAS: 35mg/m² BID d1-5,8-12<br>贝: 5mg/kg q2w</td>
<td><strong>TAS: 减量至 20mg/m²</strong><br>贝: 慎用</td>
<td>6.3%</td>
<td>5.6m</td>
<td>骨髓抑制, 恶心</td>
<td>医保</td>
</tr>
<tr>
<td><strong>奥拉帕利</strong> (Exploratory)</td>
<td><strong>[C]</strong></td>
<td>300mg BID</td>
<td><strong>减量至 200mg BID</strong></td>
<td>N/A</td>
<td>N/A</td>
<td>贫血, 疲劳</td>
<td>超适应症</td>
</tr>
</tbody>
</table>
<h3>5.2 各方案详细说明</h3>
<h4>方案 1: 氟泽雷赛 (Fulzerasib) + 西妥昔单抗 (Cetuximab)</h4>
<p><strong>证据级别</strong>: <span class="evidence-tag evidence-b">Evidence B</span> (基于同类药物及 IBI351 早期数据)<br />
<strong>治疗定位</strong>: 五线挽救治疗 (当前方案)</p>
<p><strong>给药方案</strong>:<br />
- <strong>氟泽雷赛</strong>: 600mg PO BID (需依说明书确认)<br />
- <strong>西妥昔单抗</strong>: 500 mg/m² IV Q2W</p>
<p><strong>器官功能调整</strong>:<br />
- <strong>肾功能</strong>: 氟泽雷赛尚无重度肾损数据。建议密切监测肌酐，若较基线升高 &gt;25% 暂停。西妥昔单抗无需调整。<br />
- <strong>科学依据</strong>: KRAS G12C 抑制剂单药有效率低，联合 EGFR 单抗可阻断反馈性通路激活 <span class="ref-tooltip">
              <a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/38052910" target="_blank">[R3]</a>
              <span class="ref-text">Nature Medicine 2024: Divarasib+Cetuximab</span>
            </span>。</p>
<h4>方案 2: TAS-102 (曲氟尿苷替匹嘧啶) ± 贝伐珠单抗</h4>
<p><strong>证据级别</strong>: <span class="evidence-tag evidence-a">Evidence A</span> (SUNLIGHT 研究)<br />
<strong>治疗定位</strong>: 后线标准治疗</p>
<p><strong>给药方案</strong>:<br />
- <strong>TAS-102</strong>: 标准剂量 35 mg/m² PO BID。<br />
- <strong>贝伐珠单抗</strong>: 5 mg/kg IV Q2W。</p>
<p><strong>器官功能调整</strong>:<br />
- <strong>CrCl 30-50 mL/min</strong>: <strong>必须减量</strong>。推荐起始剂量 <strong>20 mg/m² BID</strong>。FDA 标签提示中度肾损患者暴露量增加，骨髓抑制风险显著升高。</p>
<h3>5.3 禁用方案及原因</h3>
<table>
<thead>
<tr>
<th>方案</th>
<th>禁用原因</th>
<th>证据来源</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>呋喹替尼 / 瑞戈非尼</strong></td>
<td><strong>既往严重肾毒性 (AKI)</strong></td>
<td>既往病史 / 肾穿刺结果</td>
</tr>
<tr>
<td><strong>顺铂 (Cisplatin)</strong></td>
<td>肾功能不全 (eGFR &lt; 60)</td>
<td>FDA 说明书</td>
</tr>
</tbody>
</table>
<hr />
<h2>6. 器官功能与剂量 (Organ Function &amp; Dosing)</h2>
<h3>6.1 当前器官功能</h3>
<table>
<thead>
<tr>
<th>System</th>
<th>Parameter</th>
<th>Value</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Renal</strong></td>
<td><strong>Creatinine</strong></td>
<td><strong>146 μmol/L</strong></td>
<td>⚠️ <strong>Impaired (CKD 3b)</strong></td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td><strong>eGFR</strong></td>
<td><strong>~39-44 mL/min</strong></td>
<td>⚠️ <strong>Critical Constraint</strong></td>
</tr>
<tr>
<td>Hepatic</td>
<td>ALT/AST</td>
<td>Normal</td>
<td>✓ Normal</td>
</tr>
<tr>
<td>Cardiac</td>
<td>History</td>
<td>Stent</td>
<td>✓ Stable (Monitor QTc)</td>
</tr>
</tbody>
</table>
<h3>6.2 剂量调整 (关键药物)</h3>
<table>
<thead>
<tr>
<th>药物</th>
<th>标准剂量</th>
<th>当前患者建议剂量</th>
<th>调整依据</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TAS-102</strong></td>
<td>35 mg/m² BID</td>
<td><strong>20 mg/m² BID</strong></td>
<td>CrCl 30-50 mL/min 需减量</td>
</tr>
<tr>
<td><strong>奥拉帕利</strong></td>
<td>300 mg BID</td>
<td><strong>200 mg BID</strong></td>
<td>CrCl 31-50 mL/min 需减量</td>
</tr>
<tr>
<td><strong>西妥昔单抗</strong></td>
<td>500 mg/m²</td>
<td>标准剂量</td>
<td>大分子不经肾排泄</td>
</tr>
</tbody>
</table>
<h3>6.3 药物相互作用 (Oncologist Report)</h3>
<table>
<thead>
<tr>
<th>当前用药</th>
<th>风险等级</th>
<th>相互作用机制</th>
<th>处理建议</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>硝苯地平</strong></td>
<td>⚡ 中风险</td>
<td>CYP3A4 相互作用</td>
<td>监测血压 (KRASi 可能改变浓度)</td>
</tr>
<tr>
<td><strong>阿托伐他汀</strong></td>
<td>⚡ 中风险</td>
<td>CYP3A4 相互作用</td>
<td>监测肌痛 (横纹肌溶解风险)</td>
</tr>
<tr>
<td><strong>达格列净</strong></td>
<td>⚠️ 高风险</td>
<td>血容量减少</td>
<td><strong>若出现腹泻/呕吐，立即停用</strong>以防 AKI</td>
</tr>
</tbody>
</table>
<hr />
<h2>7. 治疗路线图 (Treatment Roadmap)</h2>
<h3>7.1 当前推荐方案 (详细)</h3>
<h4>方案名称: 氟泽雷赛 + 西妥昔单抗</h4>
<p><strong>证据等级</strong>: <span class="evidence-tag evidence-b">Evidence B</span><br />
<strong>治疗定位</strong>: 针对 KRAS G12C 的精准治疗</p>
<p><strong>科学依据</strong>:<br />
患者携带 KRAS G12C 突变。单纯抑制 KRAS 会导致 EGFR 信号反馈性上调。联合西妥昔单抗可双重阻断 MAPK 通路，显著提高 ORR (从单药 &lt;10% 提升至 ~30%)。</p>
<p><strong>毒性管理</strong>:<br />
1.  <strong>皮肤毒性</strong>: 预防性使用多西环素 100mg BID + 氢化可的松软膏。<br />
2.  <strong>腹泻</strong>: 备好洛哌丁胺。若出现腹泻，<strong>立即停用达格列净</strong>以保护肾功能。<br />
3.  <strong>低镁血症</strong>: 西妥昔单抗常见副作用，需每次输注前监测电解质。</p>
<p><strong>预期疗效</strong>:<br />
- 预期 ORR: ~30%<br />
- 预期 mPFS: ~5.6 个月</p>
<h3>7.2 后线选择 (详细排序)</h3>
<table>
<thead>
<tr>
<th>优先级</th>
<th>方案</th>
<th>证据等级</th>
<th>适用条件</th>
<th>关键数据</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><strong>Pan-KRAS 临床试验</strong></td>
<td><span class="evidence-tag evidence-c">Evidence C</span></td>
<td>肾功能允许入组</td>
<td>克服 G12C 耐药</td>
</tr>
<tr>
<td>2</td>
<td><strong>TAS-102 ± 贝伐</strong></td>
<td><span class="evidence-tag evidence-a">Evidence A</span></td>
<td>需严格减量</td>
<td>mPFS 5.6m (SUNLIGHT)</td>
</tr>
<tr>
<td>3</td>
<td><strong>奥拉帕利 (PARP)</strong></td>
<td><span class="evidence-tag evidence-c">Evidence C</span></td>
<td>ATM 胚系突变</td>
<td>篮子试验数据支持</td>
</tr>
</tbody>
</table>
<h3>7.3 治疗决策流程图</h3>
<div class="card-grid">
            <div class="card" style="border-left: 4px solid var(--warning);">
              <div class="card-header">当前方案 (五线)</div>
              <p><strong>氟泽雷赛 + 西妥昔单抗</strong></p>
              <ul><li>每2周查肾功能/电解质</li><li>预防皮疹</li><li>停用达格列净(若腹泻)</li></ul>
            </div>
            <div class="card" style="border-left: 4px solid var(--success);">
              <div class="card-header">若有效 (PR/SD)</div>
              <p><strong>维持治疗</strong></p>
              <ul><li>直至进展或毒性不耐受</li><li>密切监测肌酐变化</li></ul>
            </div>
            <div class="card" style="border-left: 4px solid var(--danger);">
              <div class="card-header">若进展 (PD)</div>
              <p><strong>临床试验 / TAS-102</strong></p>
              <ul><li>优先 Pan-KRAS 试验 (BGB-53038)</li><li>备选 TAS-102 (减量)</li><li>考虑奥拉帕利 (ATM靶向)</li></ul>
            </div></div>

<hr />
<h2>8. 分子复查建议 (Re-biopsy)</h2>
<p><strong>Timing</strong>: 影像学确认进展 (PD) 时。<br />
<strong>Method</strong>: 液体活检 (ctDNA) 优选（避免侵入性操作）。<br />
<strong>Panel</strong>: 广谱 NGS Panel。<br />
<strong>检测目标</strong>:<br />
1.  <strong>获得性 KRAS 突变</strong>: 如 Y96D, G12D/V (提示对 G12C 抑制剂耐药)。<br />
2.  <strong>MET 扩增</strong>: 常见的旁路耐药机制 (可联合 MET 抑制剂)。<br />
3.  <strong>MAPK 通路激活</strong>: BRAF, MAP2K1 突变。</p>
<hr />
<h2>9. 临床试验推荐 (Clinical Trials)</h2>
<p><strong>重要提示</strong>: 患者 <strong>eGFR ~40 mL/min</strong> 是入组的最大障碍。需优先筛选允许轻中度肾损 (CrCl &gt; 30-40) 的试验。</p>
<h3>推荐试验列表 (完整保留 Recruiter 报告)</h3>
<h4>试验 1 (最优先): <a href="https://clinicaltrials.gov/study/NCT06585488" class="reference" target="_blank">[NCT06585488]</a> - BGB-53038 (Pan-KRAS)</h4>
<ul>
<li><strong>NCT 编号</strong>: NCT06585488</li>
<li><strong>试验名称</strong>: BGB-53038 单药或联合治疗晚期实体瘤的 I 期研究</li>
<li><strong>阶段</strong>: Phase I</li>
<li><strong>研究药物</strong>: <strong>BGB-53038 (Pan-KRAS 抑制剂)</strong></li>
<li><strong>靶点</strong>: KRAS 突变 (包括 G12C 耐药后)</li>
<li><strong>招募状态</strong>: Recruiting</li>
<li><strong>研究中心</strong>: 北京 (医科院肿瘤/北肿)、太原</li>
<li><strong>匹配原因</strong>: Pan-KRAS 抑制剂有望克服 G12C 抑制剂产生的耐药突变。</li>
<li><strong>入组关键条件</strong>: 需确认是否接受 eGFR ~40 的患者 (I期通常较严)。</li>
</ul>
<h4>试验 2: <a href="https://clinicaltrials.gov/study/NCT06607185" class="reference" target="_blank">[NCT06607185]</a> - LY4066434 (Pan-KRAS)</h4>
<ul>
<li><strong>NCT 编号</strong>: NCT06607185</li>
<li><strong>试验名称</strong>: LY4066434 治疗 KRAS 突变实体瘤</li>
<li><strong>阶段</strong>: Phase I</li>
<li><strong>研究药物</strong>: <strong>LY4066434</strong></li>
<li><strong>靶点</strong>: KRAS 突变</li>
<li><strong>招募状态</strong>: Recruiting</li>
<li><strong>研究中心</strong>: 北京、杭州、济南、上海、天津</li>
<li><strong>匹配原因</strong>: 另一款 Pan-KRAS 抑制剂，提供更多入组机会。</li>
</ul>
<h4>试验 3: <a href="https://clinicaltrials.gov/study/NCT06825624" class="reference" target="_blank">[NCT06825624]</a> - HS-20093 (B7-H3 ADC)</h4>
<ul>
<li><strong>NCT 编号</strong>: NCT06825624</li>
<li><strong>试验名称</strong>: HS-20093 联合治疗晚期结直肠癌</li>
<li><strong>阶段</strong>: Phase I</li>
<li><strong>研究药物</strong>: <strong>HS-20093 (B7-H3 ADC)</strong></li>
<li><strong>靶点</strong>: B7-H3 (CRC 通常高表达)</li>
<li><strong>招募状态</strong>: Recruiting</li>
<li><strong>研究中心</strong>: 杭州 (浙二)</li>
<li><strong>匹配原因</strong>: ADC 药物机制不同于 TKI，可能避开激酶耐药通路。</li>
</ul>
<h4>试验 4: <a href="https://clinicaltrials.gov/study/NCT05489211" class="reference" target="_blank">[NCT05489211]</a> - Dato-DXd (TROP2 ADC)</h4>
<ul>
<li><strong>NCT 编号</strong>: NCT05489211</li>
<li><strong>试验名称</strong>: Dato-DXd 泛瘤种篮子试验</li>
<li><strong>阶段</strong>: Phase II</li>
<li><strong>研究药物</strong>: <strong>Datopotamab Deruxtecan (TROP2 ADC)</strong></li>
<li><strong>靶点</strong>: TROP2</li>
<li><strong>招募状态</strong>: Recruiting</li>
<li><strong>研究中心</strong>: 广州、长沙、重庆、杭州</li>
<li><strong>匹配原因</strong>: TROP2 ADC 在肠癌中有一定数据。</li>
</ul>
<h4>试验 5: <a href="https://clinicaltrials.gov/study/NCT05123482" class="reference" target="_blank">[NCT05123482]</a> - AZD8205 (PARP1 选择性抑制剂)</h4>
<ul>
<li><strong>NCT 编号</strong>: NCT05123482</li>
<li><strong>试验名称</strong>: AZD8205 治疗晚期实体瘤</li>
<li><strong>阶段</strong>: Phase I/II</li>
<li><strong>研究药物</strong>: <strong>AZD8205</strong></li>
<li><strong>靶点</strong>: PARP1 / ATM 突变</li>
<li><strong>招募状态</strong>: Recruiting</li>
<li><strong>研究中心</strong>: 北京、长沙、重庆</li>
<li><strong>匹配原因</strong>: 针对患者的 <strong>ATM 胚系突变</strong> 进行合成致死治疗。</li>
</ul>
<hr />
<h2>10. 局部治疗建议 (Local Therapy)</h2>
<p><strong>Current Status</strong>: 双肺多发转移，最大 2.1×1.5cm，处于进展期 (PD)。<br />
<strong>Recommendation</strong>:<br />
- 目前以全身系统治疗为主 (氟泽雷赛+西妥昔单抗)。<br />
- <strong>Oligoprogression (寡进展)</strong>: 若全身大部分病灶控制良好，仅个别肺结节增大，可考虑 <strong>SBRT (立体定向放疗)</strong> 或 <strong>射频消融 (RFA)</strong>，以延长系统治疗时间。<br />
- <strong>Symptomatic</strong>: 若出现气道压迫或咯血，考虑姑息性放疗。</p>
<hr />
<h2>11. 核心建议汇总 (Core Recommendations)</h2>
<h3>Recommended Treatment Plan</h3>
<ol>
<li>
<p><strong>Immediate (Current)</strong>: <strong>氟泽雷赛 (600mg BID) + 西妥昔单抗 (500mg/m² q2w)</strong> - <strong><span class="evidence-tag evidence-b">Evidence B</span></strong></p>
<ul>
<li><strong>Rationale</strong>: 机制最匹配的靶向方案。</li>
<li><strong>Safety</strong>: 密切监测肌酐 (每2周)。</li>
</ul>
</li>
<li>
<p><strong>Next Step (Upon Progression)</strong>:</p>
<ul>
<li><strong>Clinical Trial</strong>: 优先 Pan-KRAS (BGB-53038) 或 PARP 抑制剂试验 - <strong><span class="evidence-tag evidence-c">Evidence C</span></strong></li>
<li><strong>Standard Care</strong>: TAS-102 (需减量至 20mg/m² BID) ± 贝伐珠单抗 - <strong><span class="evidence-tag evidence-a">Evidence A</span></strong></li>
</ul>
</li>
<li>
<p><strong>Supportive Care</strong>:</p>
<ul>
<li><strong>Renal Protection</strong>: 避免脱水，腹泻时停用达格列净。</li>
<li><strong>Skin Care</strong>: 预防性使用多西环素。</li>
</ul>
</li>
</ol>
<h3>Not Recommended (Critical!)</h3>
<p><strong>DO NOT USE</strong>:<br />
1.  ❌ <strong>呋喹替尼 / 瑞戈非尼</strong>: 既往发生严重 TKI 相关肾损伤，再挑战风险极高。<br />
2.  ❌ <strong>顺铂</strong>: 绝对禁忌 (eGFR &lt; 60)。<br />
3.  ❌ <strong>PD-1 单药</strong>: MSS 且既往免疫治疗无效，单药无获益证据。</p>
<hr />
<h2>12. 参考文献 (References)</h2>
<ol>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/37870968/">PMID: 37870968 - CodeBreaK 300 (Sotorasib + Panitumumab)</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/36546659/">PMID: 36546659 - KRYSTAL-1 (Adagrasib + Cetuximab)</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/38052910/">PMID: 38052910 - Divarasib plus cetuximab in KRAS G12C CRC</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/37133585/">PMID: 37133585 - SUNLIGHT Trial (TAS-102 + Bevacizumab)</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/40715048/">PMID: 40715048 - Fulzerasib (IBI351) Early Data</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/41424250/">PMID: 41424250 - ATM mutation in CRC</a></li>
<li><a href="https://www.nccn.org/guidelines">NCCN Guidelines for Colon Cancer v1.2025</a></li>
<li><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207981s008lbl.pdf">FDA Label - Lonsurf (TAS-102)</a></li>
</ol>

      
      <div class="warning-box">
        <strong>⚠️ 安全警告</strong>
        <ul>
        
          <li>| **Renal** | **Creatinine** | **146 μmol/L** | ⚠️ **Impaired (CKD 3b)** |</li>
        
          <li>| **Renal** | **eGFR** | **~39-44 mL/min** | ⚠️ **Critical Constraint** |</li>
        
          <li>| **达格列净** | ⚠️ 高风险 | 血容量减少 | **若出现腹泻/呕吐，立即停用**以防 AKI |</li>
        
          <li>1.  ❌ **呋喹替尼 / 瑞戈非尼**: 既往发生严重 TKI 相关肾损伤，再挑战风险极高。</li>
        
          <li>2.  ❌ **顺铂**: 绝对禁忌 (eGFR &lt; 60)。</li>
        
        </ul>
      </div>
      

      
    </div>

    <footer>
      <p><strong>免责声明:</strong> 本报告仅供临床参考。具体治疗决策应由主治医师根据患者实际情况和最新临床证据综合判断。</p>
      <p>虚拟分子肿瘤委员会会诊报告 | 生成日期: 2026-01-20 16:14:11</p>
    </footer>

  </div>
</body>
</html>